New registry tracks Real-World safety of diabetes device
NCT ID NCT07197775
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This registry will follow 500 people with type 2 diabetes who have already been treated with the Endogenex System. The goal is to collect long-term safety data and see how the device performs in everyday use. Participants must agree to share their medical records and attend follow-up visits.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Endogenex System
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
May 2032
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants who have been treated with the Endogenex System.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Type 2 diabetes * Have been treated with the Endogenex System * Consented to participate in the Endogenex PULSE Registry Exclusion Criteria: * Unwilling or unable to attend study visits * Unwilling or unable to provide medical records to study sites
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites in 2 countries. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Care Access
Quincy, Massachusetts, 02169, United States
-
Care Access
Raleigh, North Carolina, 27607, United States
-
Care Access
Houston, Texas, 77054, United States
-
St Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Can mindfulness and yoga rewire diabetes habits?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- New pill takes aim at blood sugar in diabetes
- Home c-peptide tests could reveal hidden insulin production in diabetes
- Can a vegan diet shield police officers from heart disease?